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Pharmacokinetic Considerations. Pharmacokinetics is that area of pharmacology concerned
with the absorption, distribution, metabolism, and
elimination of drugs. The processes by which absorption, distribution, and elimination take place are
referred to as unit processes. These occur independently and concurrently, and involve such activities as absorption into the blood, elimination from
the blood, distribution between the blood and tissue,
inactivation in tissues, and finally, elimination from
the blood. Drug handling by the body can be
characterized by the rate for each step or, more often,
the rate of all processes. Classification of observed
kinetics for these rate processes includes first-order,
zero-order, and capacity-limited kinetics. In the
description of these processes, we will use total body
elimination as the model, as this is the way most data
are handled clinically (I).
The rate of first-order or exponential drug
elimination is proportionate solely to the amount of
drug present. The half-life is constant regardless of
the quantity present. Thus, if the dosage is doubled,
the half-life will remain the same.
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Zero-order kinetics is the term used to describe
processes where rates are constant per unit time; the
time required to rid the body of one-half the drug is
prolonged by increasing the body load. It is implied
that the rate process is limited, and the rate of
elimination is fixed.
Capacity-limited kinetics describe a situation of
a rate process being variable and between the limiting
situations of first and zero-order. As the number of
drug molecules approximates the number of
metabolic sites, for example, special mathematical
processes must be employed to describe the
responses. As drug levels rise, the rate approaches the
zero-order rate (constant amount eliminated/ time)
and as levels fall, first-order rates are approximated.
If we consider the situation of drug overdose or
intoxication, it may help to clarify these different
kinetic patterns. If zero kinetics are operative as in
alcohol, the patient will rid himself of the same
number of milligrams each hour regardless of serum
level. At high levels in the body, this constant amount
is a very small percent of body load and the rate of
decline of serum concentratiop is slow indeed. If firstorder kinetics attain, as with phenobarbital, the total
body load in the intoxicated patient will decline to
one-half in the same time as the amount in the patient
with a therapeutic amount. The situation of satura-
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tion kinetics is an intermediate between the two. An
understanding of these principles is important mainly
for preventing intoxication, for efficient alteration of
dosage, and for understanding individual variations.
While the determination of rate constants is important, other parameters are of concern. Absorption
parameters include both the rate of absorption and
the bioavailability or percentage of the drug absorbed
which reaches the active sites in the body. Distribution parameters include not only the rate of distribution but also the volume of distribution or extent to
which the drug is found outside the blood; this is
affected by protein binding. Protein binding may be
affected by disease states and other drugs.
The pharmacologic effect on the desired organ
or organ system will be dependent upon the amount
of time in the body, the time exposed to the target
organ, and the specific properties of the drug used.
The occurrence of side effects is dependent upon
similar considerations.
There are many patient variables such as individual physiology, pathology, and genetic
characteristics, as well as developmental and environmental factors which effect drug response. A
drug serum assay (drug level determination) is but a
small part of the data necessary to make an intelligent
judgment with regard to maximizing the desired
effect in therapy. Serum assay determines only the
quantity in the serum and basic assumptions must be
made in regard to the organ or organ system where
the drug is adive. Many factors affect the
relationship between serum concentration and drug
effect. An understanding of pharmacokinetic principles will result in less trial-and-error pharmacotherapy and more frequent consideration of important variables. For example, if the physician, as
his goal in treating the seizure patient, has established
that a patient should have no subsequent seizures,
then he will, with a basic understanding, be able to
prevent some of the seizures which occur during the
start-up and dosage-adjustment phases of drug
therapy; he may also avoid intoxication.
Clinical Considerations. The availability of drug
assays and pharmacokinetic data has already provided some useful information for the clinician (2).
This has increased our knowledge in four areas:
the initiation of therapy, dosage regimens, routes
of administration, and adjustment of dosage for
the four basic anticonvulsants-phenobarbital,
diphenylhydantoin (Dilantin®), primidone (Mysoline®), and ethosuximide (Zarontin®). These are

the most commonly used agents, and there are,
consequently, more pharmacokinetic data regarding
them.
Initiation of Therapy. With respect to the initiation of dosage, there is a rule of thumb that can be
helpful: If a maintenance dosage regimen is used to
initiate therapy, four times the half-life of the agent
will be required to achieve 90% of the ultimate serum
plateau. Since such a long time is required to reach
this plateau with some drugs, such as diphenylhydantoin, loading has been used, particularly to achieve
rapid therapeutic levels . Phenobarbital and
primidone, however, produce significant drowsiness,
so they are usually not "loaded." With ethosuximide, employed in the treatment of absence seizures,
loading doses are usually not used because of the
mild nature of the seizure being treated. Agents with
long half-lives, however, are, potentially, those with
which the initial dose should be larger than the
maintenance dose.
The usual starting dose for phenobarbital is 5
mg/ kg/ day in the child and about I mg/ kg/ day in
the adult. The half-life is 18-70 hours in a child (3)
and 55-120 hours in the adult (4). In general, the
younger the individual, the shorter the half-life.
The starting dose for diphen ylhydantoin is 5-8
mg/ kg/ day for the child and 4-6 mg/ kg/ day for the
adult. Once the therapeutic level is achieved, the apparent half-life is 8-12 hours. Loading of
diphenylhydantoin can be accomplished by giving
three times the maintenance dose in three divided
doses, three hours apart on the first day (5); the
second day, the usual mainten a nce dose is given.
Therapeutic levels are reached in 12 hours, and peak
serum levels are usually achieved on the third day.
Diphenylhydantoin may also be loaded intravenously
with accompanying electrocardiographic monitoring,
but not more than 50 mg/ minute should be given (6).
The initial dose ofprimidone administered is less
than the maintenance level because of the initial potent hypnotic side effects. Usually, a maintenance
dose of 20 mg/ kg/ day is sought. Switching a patient
from phenobarbital to full maintenance primidone
usually can be accomplished without producing
sedative side effects. The half-life of primidone is
short-3-12 hours (7).
The starting dose of ethosuximide is 20 mg/ kg/
day. The half-life is a mean of 66 hours in a n ad ult
and 30 hours in a child.
Dosage Regimens. Because phenobarbital and
ethosuximide have long half-lives, once-daily ad-
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ministration can be employed, and because of
diphenylhydantoin's slow absorption, it also can be
given once daily. Primidone, having a relatively short
half-life, generally, should be given three times a day,
although some patients are well treated with twicedaily dosage. Ethosuximide may have a gastric irritant effect, so some clinicians employ it in a twicedaily regimen .
Routes of Administration. Ethosuximide and
primidone can be given only orally. Phenobarbital
can be given orally, intramuscularly or intravenously.
While diphenylhydantoin can be given orally or intravenously, intramuscular administration usually
fails to release sufficient diphenylhydantoin to the
blood, when given as the usual maintenance dose.
Doubling the maintenance dose when giving it intramuscularly is satisfactory, particularly when using
this route for short-term replacement of oral therapy,
as in surgery (8) .
Adjustment of Dose. In adjusting the level of
medication, one should remember that phenobarbital
and ethosuximide are eliminated by first-order
kinetics and diphenylhydantoin, by capacity-limited
kinetics (9). Consequently, doubling the dose of
phenobarbital will double the blood level, as trebling
the dose will triple the blood level. When levels of
diphenylhydantoin are low, a similar relationship exists. At higher levels, in practice, apparently, above 10
µg / m1, the effect of capacity-limited kinetics is that
apparently relatively small dosage increments result in
greater serum level increases than is expected or
desired. Half increments are probably in order here.
The therapeutic ranges given for phenobarbital levels
are 10-50 µg / ml, for primidone are 5-20 µg / ml, and
for ethosuximide are 40-80 µg/ml. The therapeutic
range for diphenylhydantoin is 6-20 µg / ml. Recent
work indicates that low serum levels are effective in
controlling seizures particularly in children.
Compliance. While our knowledge of pharmacokinetics has increased, one larger problem ex.ists
in the area of compliance. Compliance is poor when
administration of the drug is too frequent, when multiple drugs are used on a different schedule, and when
the dosage form is unacceptable.
Three of the anticonvulsants mentioned can be
given as infrequently as once a day . This eliminates
the necessity for children to take these agents in
school. When multiple agents are given, it is relatively
easy to give all medications at one time.
Phenobarbital is available as an elixir, diphenylhydantoin and primidone, as suspensions. Where it is
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possible, the tablet form assures a more reliable
dosage intake. In the young child, all can be crushed
and given with jelly or other vehicles. Diphenylhydantoin comes as a chewable tablet, and
while it may produce more gingival hypertrophy than
the capsule, we continue to use it extensively.
Ethosuximide constitutes a rather special problem
being a liquid within a rather large gelatin capsule.
The capsule can be pricked by a pin and the liquid
mixed with juice or another vehicle by the pharmacist
or mother. One ingenious mother related that the
capsule can be frozen, then cut in half and given with
ice cream .
Memory crutches are useful. The most inexpensive is the traditional egg carton. Dial-a-packs are
also available and can be loaded by the patient with
his drug or drugs.
A new era is here. Practical pharmacokinetics,
skillfully utilized by the clinician, should aid immeasurably in producing seizure-free patients and in
reaching the goal quickly with fewer side effects.
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